Already for the fourth time, Janssen is attempting to expand reimbursement for ‘Imbruvica’ as a first-line treatment.

According to industry sources, reimbursement of Imbruvica (ibrutinib) as a first-line treatment for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL) will once again be deliberated by the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee.

Imbruvica’s reimbursement for its first-line indication, which had been deliberated by the CDDC three times from October last year to June this year, had been turned down all three times. The drug was able to receive reimbursement extensions to the second line after being lis